Deficiency symptoms include pale skin, headaches, shortness of breath, digestive-related issues, and mood changes
This formulation is intended strictly for laboratory and scientific research use
Retatrutide handles the heavy lifting on appetite and metabolism, while AOD-9604 fills a gap that no incretin-based peptide can address: direct, receptor-level stimulation of fat breakdown
A rat retinal ischemia study was conducted throughout 4 weeks, including fundoscopy, behavior presentation, tonometry, and histology assessment
Whilst clinical trial data and the MHRA-approved Summary of Product Characteristics do not list jitteriness or tremor as recognised adverse reactions, some patients report feeling shaky or anxious during treatment